Cancer drug resistance: an evolving paradigm
The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10,11].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [10]
In the citing paper
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistance across KRAS mutant cancers.57,58”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Self-citationNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Cited by
Items 501–600 of 1,016
Mitotic catastrophe and cancer drug resistance: A link that must to be broken
Denisenko, T. V., Sorokina, I. V., Gogvadze, V., & Zhivotovsky, B. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.002 · Cited by 108
Autophagy and senescence in cancer therapy
Gewirtz, D. A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24420 · Cited by 107
E1 Enzymes as Therapeutic Targets in Cancer
Barghout, S. H., & Schimmer, A. D. (2020) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000053 · Cited by 118
The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials
Hervieu, C., Christou, N., Battu, S., & Mathonnet, M. (2021) · Cancers · doi:10.3390/cancers13051092 · Cited by 122
Xiao, W., Song, M., Li, W., Huang, J., Yang, G. Y., & Wang, Y. (2021) · Theranostics · doi:10.7150/thno.59342 · Cited by 111
“In detail, the development of MDR may be classified into the following pathways (Figure 1): the changes of drug influx/efflux, the enhancement of DNA repair capacity, the alteration of drug metabolism that enables the detoxification, the mutations of drug targets, and the activation of parallel signal pathways [15, 16…”
BackgroundInfluentialPaschall, A. V., Yang, D., Lu, C., Choi, J.-H., Li, X., Liu, F., Figueroa, M., Oberlies, N. H., Pearce, C., Bollag, W. B., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402243 · Cited by 107
“Alternatively, 5-FU is the standard and most commonly used therapeutic drug for patients with advanced and metastatic CRC (24, 64).”
BackgroundYang, Q., Wang, Y., Lu, X., Zhao, Z., Zhu, L., Chen, S., Wu, Q., Chen, C., & Wang, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.3065 · Cited by 108
“However, some breast cancer patients are resistant to chemotherapy mainly due to intrinsic or acquired resistance, which could lead to failure of chemotherapy and worse treatment outcome [4, 5].”
BackgroundXia, S., Duan, W., Liu, W., Zhang, X., & Wang, Q. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02786-6 · Cited by 116
“The adaptation to chemotherapeutic drugs may be due to factors like enhanced drug efflux, drug activation/inactivation, alternations in drug targets that promote the removal of drug from the tumor, as well as the intrinsic changes of tumor cells, like enhanced stemness [92].”
BackgroundSignaling pathways in HPV‐associated cancers and therapeutic implications
Chen, J. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1823 · Cited by 118
“Patients may not respond to initial therapy (inherent drug resistance) or develop drug resistance subsequently after effective initiation (acquired resistance) [222].”
BackgroundTargeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy
Deng, R., Shen, N., Yang, Y., Yu, H., Xu, S., Yang, Y.-W., Liu, S., Meguellati, K., & Yan, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.013 · Cited by 106
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106
Genini, D., Brambilla, L., Laurini, E., Merulla, J., Civenni, G., Pandit, S., D'Antuono, R., Perez, L., Levy, D. E., Pricl, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615730114 · Cited by 106
“Thus, OPB-51602 and other STAT3i could take advantage of the Achilles’ heel represented by the specific metabolic dependencies of cancer cells and tumor-initiating cells and elicit a metabolic synthetic lethality effect (53, 54).”
BackgroundWang, T., Gantier, M. P., Xiang, D., Bean, A. G. D., Bruce, M. P., Zhou, S., Khasraw, M., Ward, A. C., Wang, L., Wei, M. Q., et al. (2015) · Theranostics · doi:10.7150/thno.11692 · Cited by 113
“Resistance to chemotherapy is a major mediator of treatment failure for solid malignancies [1].”
BackgroundPhotodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
Huang, H., Rizvi, I., Liu, J., Anbil, S. R., Kalra, A. V., Lee, H., Baglo, Y., Paz, N., Hayden, D., Pereira, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1700 · Cited by 115
“Cancer is a constantly evolving disease that relies on both microenvironmental and molecular compartments to resist and adapt to therapeutic insults (1).”
BackgroundRole of protein kinase CK2 in antitumor drug resistance
Borgo, C., & Ruzzene, M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1292-y · Cited by 113
“Similarly, the combination of a kinase inhibitor with a conventional drug is presently considered a successful strategy to avoid compensation, and this is particularly relevant in drug resistance cells, where redundant signalings are often present and amplified [11].”
BackgroundBoron Quantum Dots for Photoacoustic Imaging-Guided Photothermal Therapy
Guo, T., Tang, Q., Guo, Y., Qiu, H., Dai, J., Xing, C., Zhuang, S., & Huang, G. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c21198 · Cited by 106
Mahmoud, K. Y., Swidan, S. A., El-Nabarawi, M. A., & Teaima, M. H. M. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01309-9 · Cited by 113
Engineering lactate-modulating nanomedicines for cancer therapy
Chen, J., Zhu, Y., Wu, C., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00479h · Cited by 112
Cheng, F., Jia, P., Wang, Q., & Zhao, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.1984 · Cited by 110
“Resistance to chemotherapy and molecularly targeted kinase inhibitor therapeutics is a major obstacle facing current cancer research [37].”
Terai, H., Kitajima, S., Potter, D. S., Matsui, Y., Quiceno, L. G., Chen, T., Kim, T.-J., Rusan, M., Thai, T. C., Piccioni, F., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1904 · Cited by 107
“Despite efficacy of targeted therapy with tyrosine kinase inhibitors (TKIs) in EGFR mutant lung adenocarcinoma and other cancers, acquired resistance limits durable clinical benefit (1, 2).”
Das, C. K., Linder, B., Bonn, F., Rothweiler, F., Đikić, I., Michaelis, M., Cinatl, J. J., Mandal, M., & Kögel, D. (2018) · Neoplasia · doi:10.1016/j.neo.2018.01.001 · Cited by 112
“Drug resistance is broadly classified into two types; 1) de novo (intrinsic) drug resistance in patients that do not respond to conventional therapies, and 2) acquired resistance in patients developed during treatment [3].”
BackgroundPlatinum(IV) complex-based two-in-one polyprodrug for a combinatorial chemo-photodynamic therapy
Guo, D., Xu, S., Huang, Y., Jiang, H., Yasen, W., Wang, N., Su, Y., Qian, J., Li, J., Zhang, C., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.052 · Cited by 106
Overcoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug
Sharma, A. K., Lee, M. G., Shi, H., Won, M., Arambula, J. F., Sessler, J. L., Lee, J. Y., Chi, S., & Kim, J. S. (2018) · Chem · doi:10.1016/j.chempr.2018.08.002 · Cited by 108
Zhang, H., Zhou, Y., Cui, B., Liu, Z., & Shen, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110086 · Cited by 120
DNA Nanostructures and DNA‐Functionalized Nanoparticles for Cancer Theranostics
Nicolson, F., Ali, A., Kircher, M. F., & Pal, S. (2020) · Advanced Science · doi:10.1002/advs.202001669 · Cited by 111
Amino Acid Metabolism in Cancer Drug Resistance
Yoo, H.-C., & Han, J. M. (2022) · Cells · doi:10.3390/cells11010140 · Cited by 124
“Many underlying mechanisms of drug resistance have been proposed, as each tumor has the inherent characteristics of the tumor microenvironment (TME), the presence of cancer stem cells (CSCs), and heterogeneity in genetic and epigenetic signatures [1,2].”
BackgroundHabtemariam, S., & Lentini, G. (2018) · Biomedicines · doi:10.3390/biomedicines6020039 · Cited by 124
“By inhibiting tyrosine kinases such as mitogen-activated protein kinase kinase (MEK1/2)-ERK1/2 signaling, the therapeutic potential of imatinib, gefitinib, and sunitinib has been validated [110].”
Praharaj, P. P., Naik, P. P., Panigrahi, D. P., Bhol, C. S., Mahapatra, K. K., Patra, S., Sethi, G., & Bhutia, S. K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2990-x · Cited by 104
Han, D., Yu, T., Dong, N., Wang, B., Sun, F., & Jiang, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1289-6 · Cited by 112
“Chemotherapy resistance is an intrinsic property of GSCs, which is acquired via multiple independent mechanisms including an increase of drug efflux pumps, an enhanced DNA repair capacity, and protection against reactive oxygen species [6].”
BackgroundMetal-phenolic networks for cancer theranostics
Liu, P., Shi, X., Zhong, S., Peng, Y., Qi, Y., Ding, J., & Zhou, W. (2021) · Biomaterials Science · doi:10.1039/d0bm02064h · Cited by 106
Ševčíková, A., Izoldova, N., Števurková, V., Kasperova, B., Chovanec, M., Čierniková, S., & Mego, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010488 · Cited by 112
“Different mechanisms of drug chemoresistance have been described, related to genetic alterations, DNA damage repair, epigenetic modifications, deregulation of apoptosis, autophagy, and changes in the tumor microenvironment [1,2].”
BackgroundTreatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 116
Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies
Chaudhari, R. H., Patel, V., & Kumar, A. (2024) · Nanoscale Advances · doi:10.1039/d4na00086b · Cited by 125
“11 This section delves into various targeting strategies to enhance drug delivery, speci - cally to breast cancer cells, highlighting recent advancements and their clinical implications.”
Targeting BET bromodomain proteins in solid tumors
Sahai, V., Redig, A. J., Collier, K. A., Eckerdt, F., & Munshi, H. G. (2016) · Oncotarget · doi:10.18632/oncotarget.9804 · Cited by 115
“As the effectiveness of targeted therapies can be limited by de novo resistance or by subsequent development of resistance [91], there has been increasing interest in characterizing mechanisms of resistance to BET inhibitors.”
BackgroundProbing and regulating the activity of cellular enzymes by using DNA tetrahedron nanostructures
Zhang, Y., Deng, Y., Wang, C., Li, L., Xu, L., Yu, Y., & Su, X. (2019) · Chemical Science · doi:10.1039/c9sc01912j · Cited by 107
Advanced applications of cerium oxide based nanozymes in cancer
Feng, N., Liu, Y., Dai, X., Wang, Y., Guo, Q., & Li, Q. (2022) · RSC Advances · doi:10.1039/d1ra05407d · Cited by 111
AACR Project GENIE: 100,000 Cases and Beyond
Pugh, T. J., Bell, J. L., Bruce, J. P., Doherty, G. J., Galvin, M., Green, M. F., Hunter-Zinck, H., Kumari, P., Lenoue-Newton, M. L., Li, M. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1547 · Cited by 106
“The mechanisms underlying therapeutic resistance are complex and can include innate insensitivity, gain of secondary mutations in the drug target, and other adaptive responses (29).”
Anticancer mechanism of coumarin-based derivatives
Yadav, A. K., Shrestha, R. M., & Yadav, P. N. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116179 · Cited by 117
Hanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Beyond 3D culture models of cancer
Tanner, K., & Gottesman, M. M. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3009367 · Cited by 101
The paradigm of mutant p53-expressing cancer stem cells and drug resistance
Shetzer, Y., Solomon, H., Koifman, G., Molchadsky, A., Horesh, S., & Rotter, V. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu073 · Cited by 110
“There are three central members that have been extensively studied in relation to multidrug resistancein cancer: ABCB1 (multidrug resistance, MDR1), ABCC1 (MRP1) and ABCG2 (BCRP), which were shown to act on a broad range of conventional chemotherapy drugs (192,193) and to account for chemotherapy failure in various ca…”
BackgroundNew trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
Westover, D., & Li, F. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0275-x · Cited by 116
“Background Resistance to anti-cancer therapies is one of the most studied subjects in modern biomedical research [1, 2].”
BackgroundZhu, X., Wan, Y., Jia, H., Liu, L., & Wang, J. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201601058 · Cited by 103
Thakur, B. L., & Ray, P. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0636-8 · Cited by 105
“Cisplatin forms the first line therapy against malignancies including ovarian, breast and colorectal cancer, however, acquirement of resistance impaired therapeutic efficacy [6, 7].”
Ferroquine, the next generation antimalarial drug, has antitumor activity
Kondratskyi, A., Kondratska, K., Abeele, F. V., Gordienko, D. V., Dubois, C., Toillon, R., Slomianny, C., Lemière, S., Delcourt, P., Dewailly, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16154-2 · Cited by 114
Anticancer drug discovery from Chinese medicinal herbs
Huang, M., Zhang, L., Ding, J., & Lu, J. (2018) · Chinese Medicine · doi:10.1186/s13020-018-0192-y · Cited by 117
Controlling the speed and trajectory of evolution with counterdiabatic driving
Iram, S., Dolson, E. L., Chiel, J., Pelesko, J., Krishnan, N. P., Güngör, Ö., Kuznets-Speck, B., Deffner, S., İlker, E., Scott, J. G., et al. (2020) · Nature Physics · doi:10.1038/s41567-020-0989-3 · Cited by 126
Huynh, D. L., Sharma, N., Singh, A. K., Sodhi, S. S., Zhang, J., Mongre, R. K., Ghosh, M., Kim, N., Park, Y. H., & Jeong, D. K. (2017) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(17)30005-5 · Cited by 111
Stress management by autophagy: Implications for chemoresistance
Huang, Z., Zhou, L., Chen, Z., Nice, E. C., & Huang, C. (2016) · International Journal of Cancer · doi:10.1002/ijc.29990 · Cited by 108
“Research efforts to improve chemotherapy have had extraordinary success: however, a common clinical issue is that resistance to such anticancer agents occurs in nearly all types of cancer, which may lead to treatment failure.(1,2) The mechanism by which”
BackgroundGao, H., Song, X., Kang, T., Yan, B., Li, F., Gao, L., Ai, L., Liu, X., Yu, J., & Li, H. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s116178 · Cited by 105
“The molecular mechanisms of OXA chemoresistance are complex and multifactorial processes, such as drug influx/efflux modifications, DNA damage repair alterations, decrease of cell apoptosis and autophagy.(18,19) The activation of survival signaling pathways is a major mechanism for OXA resistance.”
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
Ghiso, E., Migliore, C., Ciciriello, V., Morando, E., Petrelli, A., Corso, S., De Luca, E., Gatti, G., Volante, M., & Giordano, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.003 · Cited by 103
“” These events are well recapitulated in vitro, where cancer cells exposed to a drug for a long period of time become resistant through mechanisms often identical to those observed in patients [1,2].”
BackgroundTherapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
Timaner, M., Letko-Khait, N., Kotsofruk, R., Benguigui, M., Beyar-Katz, O., Rachman-Tzemah, C., Raviv, Z., Bronshtein, T., Machluf, M., & Shaked, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1547 · Cited by 101
“For example, the accumulation of aberrant mutations in growth-related genes activates intrinsic pathways in tumor cells or mutations that affect drug uptake, ultimately resulting in therapy resistance (1).”
BackgroundHan, W., Shi, L., Ren, L., Zhou, L., Li, T., Qiao, Y., & Wang, H. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0019-4 · Cited by 106
Li, Y., Wang, X., Yan, J., Liu, Y., Yang, R., Pan, D., Wang, L., Xu, Y., Li, X., & Yang, M. (2019) · Biomaterials Science · doi:10.1039/c9bm00653b · Cited by 108
Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression
Meisel, C. T., Porcheri, C., & Mitsiadis, T. A. (2020) · Cells · doi:10.3390/cells9081879 · Cited by 109
“Treatments developed so far are aimed at controlling its expansion and progression, but are seldom capable of eradicating the source of the disease and preventing its reappearance [2,3].”
BackgroundMultidrug Resistance and Cancer Stem Cells in Neuroblastoma and Hepatoblastoma
Alisi, A., Cho, W., Locatelli, F., & Fruci, D. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224706 · Cited by 107
“In fact, current chemotherapeutic agents are effective against the CSCs, but in several cancers a residual pool of this subset of cells remains, determining recurrence of disease [69,113].”
BackgroundHepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer
Pothula, S. P., Xu, Z., Goldstein, D., Biankin, A. V., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.478 · Cited by 109
“Our observations are also supported by findings in other cancers, where chemotherapy-resistant cells acquired increased metastatic and self-renewal characteristics (Holohan et al, 2013).”
ResultChen, S., Wu, J., Jiao, K., Wu, Q., Ma, J., Chen, D., Kang, J., Zhao, G., Shi, Y., Fan, D., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0950-x · Cited by 101
West, J. B., Dinh, M. N., Brown, J. S., Zhang, J., Anderson, A. R., & Gatenby, R. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0006 · Cited by 106
“Acquired drug resistance can develop due to mutation or through upregulation ofmolecularmachinery (such asMDRprotein family) encoded in the human genome (32, 33).”
BackgroundMetal‐organic framework‐based cancer theranostic nanoplatforms
Yang, J., & Yang, Y. (2020) · Open Research (University of Surrey) · doi:10.1002/viw2.20 · Cited by 101
The Role of Necroptosis in ROS-Mediated Cancer Therapies and Its Promising Applications
Hsu, S., Chang, W., Lin, I., Chen, Y., Padalwar, N. B., Cheng, K., Teng, Y., Wang, C., & Chiu, C. (2020) · Cancers · doi:10.3390/cancers12082185 · Cited by 116
Emerging targetome and signalome landscape of gut microbial metabolites
Zheng, X., Cai, X., & Hao, H. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.011 · Cited by 101
Recent strategies to overcome breast cancer resistance
Khan, M. M., Yalamarty, S. S. K., Rajmalani, B. A., Filipczak, N., & Torchilin, V. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104351 · Cited by 116
Feng, X., Liu, H., Zhang, Z., Gu, Y., Qiu, H., & He, Z. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0594-1 · Cited by 99
Zhou, M., Li, L., Li, L., Lin, X., Wang, F., Li, Q., & Huang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.005 · Cited by 99
Qattan, M. Y., Khan, M. I., Alharbi, S. H., Verma, A. K., Al‐Saeed, F. A., Alduwish, M. A., & Areefy, A. A. A. (2022) · Molecules · doi:10.3390/molecules27248864 · Cited by 108
Cell membrane biomimetic nanomedicines for cancer phototherapy
Chen, M., Sun, Y., & Liu, H. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20220012 · Cited by 114
Differentiation and transdifferentiation potentials of cancer stem cells
Huang, Z., Wu, T., Liu, A. Y., & Ouyang, G. (2015) · Oncotarget · doi:10.18632/oncotarget.6098 · Cited by 103
“Increasing evidence suggests that CSCs are significantly insensitive to multiple therapeutics [113, 114].”
BackgroundRole of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
Kim, M. H., & Kim, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2412-x · Cited by 110
Chen, X., Zhang, Y., Tang, C., Tian, C., Sun, Q., Su, Z., Xue, L., Yin, Y.-F., Ju, C., & Zhang, C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.071 · Cited by 102
Perrotta, C., Cervia, D., Renzo, I. D., Moscheni, C., Bassi, M. T., Campana, L., Martelli, C., Catalani, E., Giovarelli, M., Zecchini, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01186 · Cited by 103
“Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.”
BackgroundMethodEnzyme‐Instructed Supramolecular Self‐Assembly with Anticancer Activity
Yao, Q., Huang, Z., Liu, D., Chen, J., & Gao, Y. (2018) · Advanced Materials · doi:10.1002/adma.201804814 · Cited by 100
Wang, Y., Qian, J., Yang, M., Xu, W., Wang, J., Hou, G., Ji, L., & Suo, A. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115206 · Cited by 101
Zhang, J. C., Jiang, X., Jiang, Y., Guo, M., Zhang, S., Li, J., He, J., Liu, J., Wang, J., & Ouyang, L. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.016 · Cited by 106
Wu, Z.-H., Tao, Z., Zhang, J., Li, T., Chen, N., Xie, J., Zhang, J., & Hu, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-4604-7 · Cited by 103
“Drug resistance appears to be more complex than initially thought [28], possibly involving alterations in transport pathways and metabolic cascades that decrease drug accumulation.”
BackgroundZheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 108
Zhu, Q.-N., Wang, G., Guo, Y., Peng, Y., Zhang, R., Deng, J., Li, Z., & Zhu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21121 · Cited by 100
“Over the last decades, studies have revealed multiple cellular and molecular pathways related to anthracycline chemoresistance in a variety of tumor cells including breast cancer cells [31].”
BackgroundLi, Y., Chen, W., Qi, Y., Wang, S., Li, L., Li, W., Xie, T., Zhu, H., Tang, Z., & Zhou, M. (2020) · Small · doi:10.1002/smll.202001356 · Cited by 99
Metabolomics, metabolic flux analysis and cancer pharmacology
Liang, L., Sun, F., Wang, H., & Hu, Z. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107827 · Cited by 93
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
Makaremi, S., Asadzadeh, Z., Hemmat, N., Baghbanzadeh, A., Sgambato, A., Ghorbaninezhad, F., Safarpour, H., Argentiero, A., Brunetti, O., Bernardini, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091075 · Cited by 108
“These therapies can mostly be effective at the early stage of cancer progression but might cause resistance and have severe side effects [102,103].”
BackgroundCaspase-8 in inflammatory diseases: a potential therapeutic target
Zhang, W., Zhu, C., Liao, Y., Zhou, M., Xu, W., & Zou, Z. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00646-x · Cited by 121
“This regulatory process plays a pivotal role in modulating apoptosis and necroptosis pathways, potentially offering new therapeutic avenues for treating cancer [272] and neurological disorders [273, 274].”
BackgroundZhao, Z., Zhang, L., Huang, C., Ma, S., Bu, L., Liu, J., Yu, G., Liu, B., Gutkind, J. S., Kulkarni, A. B., et al. (2016) · Scientific Reports · doi:10.1038/srep24704 · Cited by 96
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Wang, J., Hu, K., Guo, J., Cheng, F., Lv, J., Jiang, W., Lu, W., Liu, J., Pang, X., & Liu, M. (2016) · Nature Communications · doi:10.1038/ncomms11363 · Cited by 96
Júnior, R. G. D. O., Adrielly, A. F. C., Almeida, J. R. G. D. S., Grougnet, R., Thiéry, V., & Picot, L. (2018) · Fitoterapia · doi:10.1016/j.fitote.2018.02.025 · Cited by 107
Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment
Cacicedo, M. L., Islan, G. A., León, I. E., Álvarez, V. A., Chourpa, I., Allard-Vannier, É., García‐Aranda, N., Díaz‐Riascos, Z. V., Fernández, Y., Schwartz, S., et al. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.06.056 · Cited by 101
“MDR can be acquired during treatment due to an adaptive response of cancer cells to cytotoxic drugs, leading to treatment failure [7,8].”
BackgroundAbbas, S. Y., Al‐Harbi, R. A. K., & El‐Sharief, M. A. M. S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112363 · Cited by 96
Targeting epigenetic regulatory machinery to overcome cancer therapy resistance
Guo, L., Lee, Y.-T., Zhou, Y., & Huang, Y. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.022 · Cited by 92
Wang, Y., Zhang, L., Zhao, G., Zhang, Y., Zhan, F., Chen, Z., He, T., Cao, Y., Hao, L., Wang, Z., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01201-y · Cited by 99
“Due to tumor heterogeneity, the phenotypic diversity of tumor cells and activation of antiapoptotic pathways leading to tumor resistance to apoptosis, PDT cannot effectively eradicate tumors via a single mode of cell death [21, 22].”
BackgroundLenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Qin, Y., Han, S., Yu, Y., Ding, Q., Ran, M., Yang, M., Liu, Y., Li, Y., Lu, L., Liu, Y., et al. (2024) · Liver International · doi:10.1111/liv.15953 · Cited by 112
“111 Additionally, the activation of HIFs in the TME regulates the expression of glycolytic enzymes, including 6- phosphofructo- 2-kinase/ fructose-2,6- bisphosphatase-3 (PFKFB3), hexokinase 2 (HK2), triose phosphate isomerase, and glyceraldehyde- 3-phosphate dehydrogenase (GAPDH); these enzymes…”
Nanomaterials Enhanced Sonodynamic Therapy for Multiple Tumor Treatment
Yang, M., Wang, X., Peng, M., Wang, F., Hou, S., Xing, R., & Chen, A. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01666-8 · Cited by 112
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
“With the range cancer drug resistance mechanisms, it seems unlikely that the dream of a ‘magic bullet’ to cure cancer will ever be realized [119].”
BackgroundInfluentialCeballos, M. P., Rigalli, J. P., Ceré, L. I., Semeniuk, M., Catania, V. A., & Ruiz, M. L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180105103637 · Cited by 101
In Situ shRNA Synthesis on DNA–Polylactide Nanoparticles to Treat Multidrug Resistant Breast Cancer
Ni, Q., Zhang, F., Zhang, Y., Zhu, G., Wang, Z., Teng, Z., Wang, C., Yung, B. C., Niu, G., Lu, G., et al. (2018) · Advanced Materials · doi:10.1002/adma.201705737 · Cited by 98
NoncoRNA: a database of experimentally supported non-coding RNAs and drug targets in cancer
Li, L., Wu, P., Wang, Z., Meng, X., Zha, C., Li, Z., Qi, T., Zhang, Y., Han, B. R., Li, S., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00849-7 · Cited by 95
A Self-Evaluating Photothermal Therapeutic Nanoparticle
Wang, Y., Du, W., Zhang, T., Zhu, Y., Ni, Y., Wang, C., Raya, F. M. S., Zou, L., Wang, L., & Liang, G. (2020) · ACS Nano · doi:10.1021/acsnano.9b10144 · Cited by 95
Targeting ferroptosis synergistically sensitizes apoptotic sonodynamic anti-tumor nanotherapy
Zhou, L., Dong, C., Ding, L., Feng, W., Yu, L., Cui, X., & Chen, Y. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101212 · Cited by 97
miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression
Mu, W., Hu, C., Zhang, H., Qu, Z., Cen, J., Qiu, Z., Li, C., Ren, H., Li, Y., He, X., et al. (2015) · Cell Research · doi:10.1038/cr.2015.23 · Cited by 99
Cui, D., Dai, J., Keller, J. M., Mizokami, A., Xia, S., & Keller, E. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0242 · Cited by 101
“Multiple mechanisms have been suggested to contribute to the development of docetaxel resistance (40).”
BackgroundQuantitative interactome analysis reveals a chemoresistant edgotype
Chavez, J. D., Schweppe, D. K., Eng, J. K., Zheng, C., Taipale, A., Zhang, Y., Takara, K., & Bruce, J. E. (2015) · Nature Communications · doi:10.1038/ncomms8928 · Cited by 94
Kumar, K., Raza, S. S., Knab, L. M., Chow, C. R., Kwok, B., Bentrem, D. J., Popovic, R., Ebine, K., Licht, J. D., & Munshi, H. G. (2015) · Scientific Reports · doi:10.1038/srep09489 · Cited by 94
Metadata
- Authors
- Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 714-726
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042619042
- Cited by
- 4,681
- References
- 178
- Citations by year
- 2026: 322 · 2025: 358 · 2024: 327 · 2023: 356 · 2022: 364 · 2021: 442 · 2020: 465 · 2019: 460 · 2018: 433 · 2017: 385 · 2016: 342 · 2015: 276 · 2014: 135 · 2013: 4
- FWCI
- 26.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Cancer Research UK (13172, 13721, C212/A13721)
- Public Health Agency (RRG/3261/05)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- chemoresistance, targeted therapy, drug target alterations, cell death evasion, predictive biomarkers, patient stratification, high-throughput screening, preclinical models
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, Autophagy, Biological Transport, Biotransformation, DNA Damage, DNA Repair, Humans, Models, Biological, Mutation, Neoplasm Proteins, Neoplastic Stem Cells, Drug Design, Gene Expression Regulation, Neoplastic, Apoptosis, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Gene Silencing, Apoptosis Regulatory Proteins, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.